PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
BACKGROUND: Immune checkpoint inhibition is effective in several cancers. Expression of programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could provide insights into selection of patients for immune checkpoint inhibition.
METHODS: Whole blood was collected at serial timepoints from metastatic breast cancer patients and healthy donors for circulating tumor cell (CTC) and platelet PD-L1 analysis with a phycoerythrin-labeled anti-human PD-L1 monoclonal antibody (Biolegend clone 29E.2A3) using the CellSearch® assay. CTC PD-L1 was considered positive if detected on at least 1% of the cells; platelet PD-L1 was considered positive if ≥100 platelets per CellSearch frame expressed PD-L1.
RESULTS: A total of 207 specimens from 124 metastatic breast cancer patients were collected. 52/124 (42%) samples at timepoint-1 (at or close to time of progressive disease) had ≥5 CTC/7.5ml whole blood. Of those, 21 (40%) had positive CTC PD-L1. In addition, platelet PD-L1 expression was observed in 35/124 (28%) at timepoint-1. Platelet PD-L1 was not detected in more than 70 specimens from 12 healthy donors. Platelet PD-L1 was associated with ≥5 CTC/7.5ml whole blood (p = 0.0002), less likely in patients with higher red blood cell counts (OR = 0.72, p<0.001) and a history of smoking tobacco (OR = 0.76, p<0.001). Platelet PD-L1 staining was not associated with tumor marker status, recent procedures or treatments, platelet-affecting drugs, or CTC PD-L1 expression.
CONCLUSION: PD-L1 expression was found in metastatic breast cancer patients on both CTC and platelets in an independent fashion. Inter-patient platelet PD-L1 expression was highly heterogeneous suggesting that it is a biological event associated with cancer in some but not all patients. Taken together, our data suggest that CTC and platelet PD-L1 expression could play a role in predicting which patients should receive immune checkpoint inhibition and as a pharmacodynamics biomarker during treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
PloS one - 16(2021), 11 vom: 15., Seite e0260124 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Darga, Elizabeth P [VerfasserIn] |
---|
Links: |
---|
Themen: |
B7-H1 Antigen |
---|
Anmerkungen: |
Date Completed 29.12.2021 Date Revised 29.12.2021 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0260124 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM333183134 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM333183134 | ||
003 | DE-627 | ||
005 | 20231225221125.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0260124 |2 doi | |
028 | 5 | 2 | |a pubmed24n1110.xml |
035 | |a (DE-627)NLM333183134 | ||
035 | |a (NLM)34780566 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Darga, Elizabeth P |e verfasserin |4 aut | |
245 | 1 | 0 | |a PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.12.2021 | ||
500 | |a Date Revised 29.12.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Immune checkpoint inhibition is effective in several cancers. Expression of programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could provide insights into selection of patients for immune checkpoint inhibition | ||
520 | |a METHODS: Whole blood was collected at serial timepoints from metastatic breast cancer patients and healthy donors for circulating tumor cell (CTC) and platelet PD-L1 analysis with a phycoerythrin-labeled anti-human PD-L1 monoclonal antibody (Biolegend clone 29E.2A3) using the CellSearch® assay. CTC PD-L1 was considered positive if detected on at least 1% of the cells; platelet PD-L1 was considered positive if ≥100 platelets per CellSearch frame expressed PD-L1 | ||
520 | |a RESULTS: A total of 207 specimens from 124 metastatic breast cancer patients were collected. 52/124 (42%) samples at timepoint-1 (at or close to time of progressive disease) had ≥5 CTC/7.5ml whole blood. Of those, 21 (40%) had positive CTC PD-L1. In addition, platelet PD-L1 expression was observed in 35/124 (28%) at timepoint-1. Platelet PD-L1 was not detected in more than 70 specimens from 12 healthy donors. Platelet PD-L1 was associated with ≥5 CTC/7.5ml whole blood (p = 0.0002), less likely in patients with higher red blood cell counts (OR = 0.72, p<0.001) and a history of smoking tobacco (OR = 0.76, p<0.001). Platelet PD-L1 staining was not associated with tumor marker status, recent procedures or treatments, platelet-affecting drugs, or CTC PD-L1 expression | ||
520 | |a CONCLUSION: PD-L1 expression was found in metastatic breast cancer patients on both CTC and platelets in an independent fashion. Inter-patient platelet PD-L1 expression was highly heterogeneous suggesting that it is a biological event associated with cancer in some but not all patients. Taken together, our data suggest that CTC and platelet PD-L1 expression could play a role in predicting which patients should receive immune checkpoint inhibition and as a pharmacodynamics biomarker during treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a B7-H1 Antigen |2 NLM | |
650 | 7 | |a CD274 protein, human |2 NLM | |
700 | 1 | |a Dolce, Emily M |e verfasserin |4 aut | |
700 | 1 | |a Fang, Fang |e verfasserin |4 aut | |
700 | 1 | |a Kidwell, Kelley M |e verfasserin |4 aut | |
700 | 1 | |a Gersch, Christina L |e verfasserin |4 aut | |
700 | 1 | |a Kregel, Steven |e verfasserin |4 aut | |
700 | 1 | |a Thomas, Dafydd G |e verfasserin |4 aut | |
700 | 1 | |a Gill, Anoop |e verfasserin |4 aut | |
700 | 1 | |a Brown, Martha E |e verfasserin |4 aut | |
700 | 1 | |a Gross, Steven |e verfasserin |4 aut | |
700 | 1 | |a Connelly, Mark |e verfasserin |4 aut | |
700 | 1 | |a Holinstat, Michael |e verfasserin |4 aut | |
700 | 1 | |a Cobain, Erin F |e verfasserin |4 aut | |
700 | 1 | |a Rae, James M |e verfasserin |4 aut | |
700 | 1 | |a Hayes, Daniel F |e verfasserin |4 aut | |
700 | 1 | |a Paoletti, Costanza |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 16(2021), 11 vom: 15., Seite e0260124 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2021 |g number:11 |g day:15 |g pages:e0260124 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0260124 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2021 |e 11 |b 15 |h e0260124 |